Patients taking infliximab should be monitored for any new or changed skin lesions, the TGA has advised. In its latest Medicines Safety Update the regulatory body said product information had been updated to reflect a heightened risk of non-melanoma skin cancers. The changes included updating the ‘Precautions’ section to include the statement ‘Psoriasis patients should be ...
Monitor patients on infliximab for skin cancers
3 Aug 2015